Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Janet, Maleski"'
Autor:
Geoffrey T. Gibney, Omid Hamid, Jose Lutzky, Anthony J. Olszanski, Tara C. Mitchell, Thomas F. Gajewski, Bartosz Chmielowski, Brent A. Hanks, Yufan Zhao, Robert C. Newton, Janet Maleski, Lance Leopold, Jeffrey S. Weber
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Abstract Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-
Externí odkaz:
https://doaj.org/article/5099b0af01e64192a7b84fc9a960caa6
Autor:
Michael Smith, Janet Maleski, Lance Leopold, Robert Newton, Sherry Owens, Xiaohua Gong, Chuan Tian
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/621844b1162a4f868df3e22d0bc1d733
Autor:
Yufan Zhao, Ani Sarkis Balmanoukian, Xiaohua Gong, Lance Leopold, Jeffrey S. Wasser, Anthony J. Olszanski, Thomas F. Gajewski, Janet Maleski, Tara C. Mitchell, David Smith, Todd M. Bauer, Omid Hamid, Emmett V. Schmidt, Jason J. Luke
Publikováno v:
Journal of Clinical Oncology
Purpose Tumors may evade immunosurveillance through upregulation of the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Epacadostat is a potent and highly selective IDO1 enzyme inhibitor. The open-label phase I/II ECHO-202/KEYNOTE-037 trial evaluated ep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda78645338f65e29707ad7c012dfd6b
https://doi.org/10.1200/jco.2018.78.9602
https://doi.org/10.1200/jco.2018.78.9602
Autor:
Richard Schaub, Thomas F. Gajewski, Jason Clark, Peggy Scherle, Jack G. Shi, Gregory L. Beatty, Lance Leopold, Janet Maleski, Robert C. Newton, Kevin Bowman, Peter J. O'Dwyer
Publikováno v:
Clinical Cancer Research. 23:3269-3276
Purpose: Indoleamine 2,3-dioxygenase-1 (IDO1) catalyzes the degradation of tryptophan to N-formyl-kynurenine. Overexpressed in many solid malignancies, IDO1 can promote tumor escape from host immunosurveillance. This first-in-human phase I study inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56b016af28d332f259d5e900d8ef4c73
https://doi.org/10.1158/1078-0432.ccr-16-2272
https://doi.org/10.1158/1078-0432.ccr-16-2272
Autor:
Ana Arance, Thomas F. Gajewski, Christian Caglevic, Mark M. Jones, Janet Maleski, Caroline Robert, Lev V. Demidov, Omid Hamid, Tae Min Kim, Scott J. Diede, Stéphane Dalle, Tara C. Mitchell, Matteo S. Carlino, Reinhard Dummer, Georgina V. Long, James R. Anderson, Jean-Jacques Grob, James Larkin
Publikováno v:
Ann Transl Med
Summary Background Immunotherapy combination treatments can improve patient outcomes. Epacadostat, an IDO1 selective inhibitor, and pembrolizumab, a PD-1 inhibitor, showed promising antitumour activity in the phase 1–2 ECHO-202/KEYNOTE-037 study in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::994d50fe36f67262fd59a66df91baccb
https://www.zora.uzh.ch/id/eprint/172887/
https://www.zora.uzh.ch/id/eprint/172887/
Autor:
Yufan Zhao, Lance Leopold, Geoffrey T. Gibney, Tara C. Mitchell, Brent A. Hanks, Robert C. Newton, Thomas F. Gajewski, Jeffrey S. Weber, Janet Maleski, Anthony J. Olszanski, Bartosz Chmielowski, Omid Hamid, Jose Lutzky
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Epacadostat is a potent inhibitor of the immunosuppressive indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. We present phase 1 results from a phase 1/2 clinical study of epacadostat in combination with ipilimumab, an anti-cytotoxic T-lymphocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::070a267b92ea7221bf6b7632fd52a6a3
https://doi.org/10.1186/s40425-019-0562-8
https://doi.org/10.1186/s40425-019-0562-8
Autor:
Scott J. Diede, Reinhard Dummer, Mark M. Jones, Caroline Robert, Lev V. Demidov, James Larkin, Omid Hamid, Tae Min Kim, Georgina V. Long, Jean-Jacques Grob, Tara C. Mitchell, Janet Maleski, Ana Arance, James R. Anderson, Christian Caglevic, Stéphane Dalle, Matteo S. Carlino, Thomas F. Gajewski
Publikováno v:
SSRN Electronic Journal.
Background: Immunotherapy combination treatments may improve patient outcomes. Epacadostat, an indoleamine 2,3-dioxygenase 1 (IDO1) selective inhibitor, and pembrolizumab, a programmed death protein (PD)-1 inhibitor, showed promising antitumour activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e3c7630dcd1422b6cc3a19bf4a24bb7
https://doi.org/10.2139/ssrn.3327362
https://doi.org/10.2139/ssrn.3327362
Publikováno v:
The Journal of Clinical Pharmacology. 57:720-729
Epacadostat (EPA, INCB024360) is a selective inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) and is being developed as an orally active immunotherapy to treat advanced malignancies. In the first clinical study investigating the safety, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d88c83cd53275855e84e788ead3ef5d9
https://doi.org/10.1002/jcph.855
https://doi.org/10.1002/jcph.855
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 47(7)
Epacadostat (EPAC) is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor that has been examined in multiple clinical trials. The substrate for IDO1 is tryptophan and there is a theoretical concern that inhibition of IDO1 may increase the concentration
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d4a6fb844f9bf11ec88a1ad471e53e
https://pubmed.ncbi.nlm.nih.gov/31010933
https://pubmed.ncbi.nlm.nih.gov/31010933
Autor:
Jack G, Shi, Kevin J, Bowman, Xuejun, Chen, Janet, Maleski, Lance, Leopold, Swamy, Yeleswaram
Publikováno v:
Journal of clinical pharmacology. 57(6)
Epacadostat (EPA, INCB024360) is a selective inhibitor of the enzyme indoleamine 2,3-dioxygenase 1 (IDO1) and is being developed as an orally active immunotherapy to treat advanced malignancies. In the first clinical study investigating the safety, t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0669908fe7e70a5409e40b13a5dc86db
https://pubmed.ncbi.nlm.nih.gov/27990653
https://pubmed.ncbi.nlm.nih.gov/27990653